At the time of writing this commentary, the death toll from the COVID-19 epidemic caused by coronavirus SARS-CoV-2, which emerged in late December 2019, has surpassed the combined death toll of the SARS (Severe Acute Respiratory Syndrome) epidemic of 2002-2003 and the MERS (Middle East Respiratory Syndrome) epidemic of 2013 combined. This epidemic seems to be spreading at an exponential rate, with a doubling period of 1.8 days, and there are fears that it might progress to pandemic scales. Yet, no SARS-CoV-2 therapeutics are presently available, albeit some treatment options which await validation have been published, including several broad spectrum antivirals such as favipiravir and remdesivir, the anti-malaria drug chloroquine, and a traditional Chinese herbal formula. The ultimate solution is, obviously, developing a SARS-CoV-2 vaccine. However, vaccines for the SARS-CoV developed since its outbreak 18 years ago have not materialized to an approved product. In addition, there have been concerns about vaccine-mediated enhancement of disease, for example, due to pulmonary immunopathology upon challenge with SARS-CoV. Moreover, even once a vaccine is approved for human use, high virus mutation rates mean that new vaccines may need to be developed for each outbreak, similarly to the situation with new annual influenza vaccines. Below, I describe an alternative option which, if proven to be effective, would allow a rapid application in the clinic.